PAX6 and cystic fibrosis: Supporting this model are CFTR complementation experiments in CF PDEs and PTEN and GSK3β chemical inhibition experiments in WT PDEs, which either reserve or promote CF-associated changes in PDX1, SOX9, PAX6, and/or NKX6.1 expression.